SURPASS 2 trial Tirzepatide versus Semaglutide for weight loss in diabetic patients (weight loss in kg and by percentage of body weight), lipid levels Tirzepatide is licensed for weight loss and treatment of obesity under the brand name Zepbound, while Semaglutide is licensed under the brand name Semaglutide
Future Directions in Therapy The future of liver-targeted metabolic therapy is promising
[DOI] [PubMed] [Google Scholar] 227.Redman LM, de Jonge L, Fang X, Gamlin B, Recker D, Greenway FL, et al
While mice lacking adipose HSL can achieve near normal rates of TAG hydrolysis, these animals display severely blunted DAG lipase activity, and as a result, DAG accumulates in adipose tissues (44)
The insulin response is glucose-dependent
Obesity and its management in primary care setting